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Steroid-free immunosuppression in kidney transplantation
has been gaining popularity over the past decade, as
documented by a continuous and steady rise in the number
of kidney transplant patients discharged on steroid-free
regimens. This increased interest in steroid-free
immunosuppression is fueled by the recognition that half of
transplant loss is related to patient death due to
cardiovascular disease and/or infectious complications and
that the long-term use of steroids contributes to such
elevated cardiovascular morbidity and mortality. The
availability of newer and more potent immunosuppressive
agents has furthered such interest. Many clinical trials over
the past two decades have demonstrated the feasibility of
steroid-free regimens, at the expense of a slight increase in
the rate of acute rejection, which is an important end point in
any clinical trial of relatively short duration. The largest
epidemiological study to date has reassured the transplant
community that the selective use of steroid-free
immunosuppression in kidney transplant patients provides
no inferior outcome in patient and graft survival at
intermediate term. Steroid-free regimens have the potential
to improve cardiovascular risk profile. The challenges that
remain are to identify the subset of kidney transplant
patients who may not benefit from steroid-free
immunosuppression and to demonstrate the survival
advantage of steroid-free immunosuppresion in suitable
kidney transplant candidates.
Kidney International (2009) 76, 825–830; doi:10.1038/ki.2009.248;
published online 22 July 2009
KEYWORDS: cardiovascular risk; graft survival; kidney transplant; new-onset
diabetes; patient survival; steroid-free immunosuppression
Steroids have been a part of any immunosuppressive regimen
since the beginning of kidney transplantation because of their
anti-inflammatory and immunosuppressive property, in
addition to their ability to reverse acute rejection.1–4
However, it was soon recognized that the long-term use of
steroids was associated with a wide range of adverse effects,
even at a relatively low dose.5 These adverse effects include
worsening hypertension, worsening dyslipidemia, new-onset
diabetes, osteoporosis, avascular necrosis, susceptibility to
infection, and so on. Many of these are responsible for a
persistently elevated cardiovascular risk burden in kidney
transplant patients, and therefore, excessive mortality.6 In
fact, the recognition of steroid-associated adverse effects has
perpetuated the effort of sparing steroids from immunosup-
pression regimens over the past three decades.7–9 With the
introduction of cyclosporine (CsA) in the early 1980s,
tacrolimus (Tac) and mycophenolate mofetile (MMF) in
the mid 1990s, and the availability of various induction
agents, the interest in sparing steroids has grown more
intense. This has led to multiple reports of experiences with
randomized and/or no randomized clinical trials.
EARLY EXPERIENCE WITH STEROID WITHDRAWAL
The very initial systematic attempt to wean kidney transplant
patients off steroids came during the late 1980s and early
1990s when CsA became widely used as the main immuno-
suppressant, either alone or in combination with azathiopr-
ine (AZA). Griffin et al.10 conducted one of the very early
randomized and controlled clinical trials comparing CsA
monotherapy with CsA plus low-dose maintenance steroids
and found an equal renal outcome but a higher incidence of
CsA nephrotoxicity in the CsA monotherapy group. Patients
in the CsA monotherapy group had significantly lower
infectious and cosmetic complications. However, more than
50% of patients eventually returned to a steroid-containing
regimen. Schulak et al.9 presented their experience with early
steroid withdrawal in patients treated with anti-lymphocyte
globulin, CsA, and AZA. Although there were no differences
in patient and graft survival, patients who had steroids
withdrawn did experience more frequent and severe acute
rejection episodes. Sinclair11 reported the experience from a
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multicenter randomized trial comparing low-dose steroids
with placebo in 523 kidney transplant patients receiving a
CsA maintenance regimen. Although graft survival was
similar between the two groups within the first 500 days,
after more than 6 years of follow-up, graft survival was
significantly worse in patients on no steroids. There was also
poorer adherence to the test drug in the placebo group, with
more than half of the patients eventually dropping out of the
assigned study drug protocols.
Two meta-analyses performed by Hricik et al.8 in the early
1990s and by Kasiske et al.12 in early 2000 summarized the
experience of steroid withdrawal, mostly with CsA-based
immunosuppression during the late 1980s and early 1990s.
The results of thousands of patients from 7 different studies
in one case and from 10 different studies in another
confirmed the findings of individual studies. Steroid with-
drawal was associated with a greater proportion of patients
experiencing acute rejection, and the relative risk for graft
failure was 40% higher in patients withdrawn from steroids
when follow-up extended to 5 years and beyond.
Thus, these early observations clearly showed an increased
incidence in acute rejection in patients withdrawn from or
not receiving steroids. As high as 50% of patients initially
withdrawn from steroids had to return to steroids. This could
represent a serious drawback of steroid withdrawal, as the
increased long-term risk for graft failure may counterbalance
any potential benefit of steroid withdrawal. As a consequence
of these findings, the interest in steroid-free immunosup-
pression was dampened among many transplant physicians
and surgeons in the transplant community.
RECENT EXPERIENCES WITH STEROID WITHDRAWAL
With the introduction of more potent immunosuppressive
agents, such as MMF, Tac, sirolimus, and newer induction
agents such as anti-thymocyte globulin and anti-IL2 receptor
antibodies in the 1990s, the overall incidence of acute
rejection has decreased during this time span in patients
treated with steroid-containing immunosuppressive regi-
mens.13–16 At the same time, there has been a renewed
enthusiasm in steroid-free immunosuppression. This is
shown by the continuous increase in the numbers of patients
on a steroid-free immunosuppressive regimen at the time
of discharge from the hospital after transplant surgery
(Figure 1).17
Ahsan et al.18 presented the results of a multicenter,
randomized, and double-blind steroid withdrawal trial at 3
months after transplant, in patients receiving a combination
of CsA and MMF. Although patient and graft survival were
no different at 1 year, there was a significant increase in acute
rejection or treatment failure (9.8% with steroids and 30.8%
without steroids, Po0.001). In particular, the risk of
treatment failure was much higher for blacks (39.6%) than
for non-blacks (16.0%). Furthermore, patients withdrawn
successfully from steroids had a higher serum creatinine.
Vanrenterghem et al.19 conducted a similar trial in Europe
involving 500 patients, with half of them having steroids
discontinued at 3 months. The rate of biopsy-proven acute
rejection was higher in the steroid withdrawal group at 6
months (23 vs 14%, respectively, P¼ 0.008) and 12 months
(25 vs 15%, respectively), although the graft loss at 12
months was similar (5 vs 4%, respectively). Neither of these
studies involved a universal use of antibody induction.
In the late 1990s, it was increasingly recognized that late
posttransplant steroid withdrawal was associated with an
increased incidence in acute rejection in some recipients. It
was also recognized that the chronic use of steroids may have
sensitized lymphocytes by upregulating the expression of
cytokine receptors in the surface membrane so that with-
drawal in a late stage would have resulted in the stimulation
of those lymphocytes.20 Finally, late steroid withdrawal may
not prevent steroid-related complications, at least in some
aspects. With these considerations in mind, Matas et al. from
the University of Minnesota conducted a pilot study of rapid
discontinuation of steroids within the first 5 days. Thymo-
globulin was the induction agent; CsA and MMF were
maintenance medications.21 Compared with the historical
controls of CsA/AZA/P and CsA/MMF/P regimens without
the use of an induction agent, there was no difference in
1-year patient and graft survival. Only 10% of patients had a
biopsy-proven acute rejection that was not different from
that of historical controls. However, 25% of patients returned
to steroids 5 to 17 months after transplant.
In a multicenter, randomized early steroid withdrawal trial
reported by Vincenti et al., anti-IL2 receptor antibody was
used as the induction agent, followed by CsA and MMF as
the maintenance regimen. It yielded results comparable with
those of the steroid-containing regimen regarding the
incidence of acute rejection at 12 months (20 vs 16%, non
significant).22 Patient and graft survival were similarly good
in both groups, but 28% of patients from the steroid
withdrawal group returned to steroid-containing regimens at
6 months after transplantation.
Most recently, the Freedom trial compared steroid-free
and early steroid withdrawal with a standard chronic steroid-
containing regimen using an anti-IL2 receptor antibody as
the induction agent and a combination of CsA/MPA as
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Figure 1 |The trend of the use of steroid-free
immunosuppression at discharge within the US transplant
centers between 2000 and 2006.
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maintenance therapy.23 At 12 months, biopsy-proven acute
rejection occurred significantly more often and earlier in
steroid-free and steroid withdrawal groups (31.5% in steroid-
free, 26.1% in steroid withdrawal and 14.7% in standard
steroid groups, P¼ 0.007 and P¼ 0.046 for steroid-free and
steroid withdrawal groups vs standard steroid group,
respectively). Patient and graft survival were no different
among the groups. Renal function was no different.
On the other hand, the experience using a combination of
CsA and sirolimus suggested that lower rates of acute
rejection could be achieved without the use of steroids. Rajab
et al.24 reported their experience with this combination in
301 primary kidney transplant patients. The first year
incidence of acute rejection was 4.9% in the steroid-free
group compared with 9.4% in a historical cohort of primary
kidney transplant patients with a steroid-containing regimen
(Po0.05). Patient and death censored graft survival at 1 year
were 93.1% and 98.1%, respectively.
Since the introduction of Tac into the armamentarium of
maintenance immunosuppressive medications, several clin-
ical trials have shown a lower rate of acute rejection
compared with CsA regimens.25–28 Rostaing et al.29 reported
the outcome of a multicenter European study comparing the
regimens of Tac and MMF with and without maintenance
steroids. After 6 months of follow-up, the incidence of acute
rejection was identical at 16.5% in both groups, involving a
total of 538 patients. The severity of acute rejection was also
identical. However, the steroid withdrawal group received
induction therapy with an anti-IL2 receptor antibody,
whereas the steroid-containing group did not. The major
drawback of this study was a too short follow-up time and
the differential use of induction agent.
After initially reporting their pilot experience with rapid
steroid withdrawal in CsA- and MMF-treated patients, Matas
et al.30,31 further extended their experience into a large cohort
of patients to include Tac and sirolimus. In spite of not being
randomized and uncontrolled, their experience clearly showed
that, with the use of induction therapy, early steroid
withdrawal produced acceptable short- and intermediate-term
outcomes with regard to both patient and graft survival, as
well as the incidence of acute rejection during the 5-year study
period. Furthermore, compared with historical controls,
steroid withdrawal patients experienced significantly fewer
complications related to the long-term use of steroids such as
cataracts, new-onset diabetes, avascular necrosis, and fractures.
Kumar et al.32,33 reported their experience with steroid
withdrawal 2 days after transplant, using an anti-IL2 receptor
antibody as the induction agent and Tac, combined either
with MMF or sirolimus, as the maintenance regimen. More
than half of their patients were African-American. A
surveillance biopsy was performed on all their patients at 1,
6, 12, 24, and 36 months after transplant. Patient and graft
survival were similar at 3 years. Clinical acute rejection was
diagnosed in 14% of steroid-treated and in 16% of steroid
withdrawal patients at 1 year (P¼NS). Subclinical acute
rejection and chronic allograft nephropathy, diagnosed by
surveillance biopsies, were higher in both groups. However,
no difference existed between steroid-treated and steroid
withdrawal patients over 3 years. Weight gain and incidence
of new-onset diabetes were significantly lower in steroid
withdrawal patients (change in body mass index 0.3 vs 4.4,
respectively, over 3 years, P¼ 0.04, and new-onset diabetes
(NODAT) 4 vs 21%, respectively, at 3 years, Po0.01).
Similarly, a serious infection requiring hospitalization was
lower in the steroid withdrawal group (18 vs 35%, P¼ 0.05).
African-American kidney transplant patients are tradi-
tionally considered to be at high risk for immunological
complications. Steroid withdrawal in this group of patients
was typically complicated by a higher rejection rate and
poorer graft survival.18,34 However, African-American pa-
tients may benefit more from steroid withdrawal-related
improvement in cardiovascular risk reduction, such as a
reduced incidence of new-onset diabetes and weight gain. By
using the combination of Tac and sirolimus, Hricik et al.35
have shown that steroids could be successfully withdrawn
with a low incidence of acute rejection. Gruber et al. achieved
a similar outcome using a combination of Tac and MMF.36
More recently, Woodle et al.37 published their experience
of early steroid withdrawal in patients receiving Tac and
MMF. Their study involved 386 patients from multiple
centers, randomized to rapid steroid withdrawal (191
patients) and to chronic low-dose steroids (195 patients)
with a 5-year follow-up. They excluded highly sensitized
patients (pPRAX50% and/or cPRAX25%). Steroid with-
drawal was completed within 7 days after transplant.
Induction was used but the choice of agents, an anti-IL2
receptor antibody or thymoglobulin, was determined by
individual centers. After a 5-year follow-up, they found no
difference between the two study groups in the composite
primary end point of death, graft loss, and moderate–severe
acute rejection. Biopsy-proven acute rejection, however, was
higher in the steroid withdrawal group (17.8 vs 10.8%,
respectively, over 5 years, Kaplan–Meier analysis, log-rank
P¼ 0.042). When sub-analysis was performed to determine
the effects of the induction agents used, the magnitude in the
difference of acute rejection was higher in patients who
received an anti-IL2 receptor antibody (24.2% in steroid
withdrawal and 11.9% in chronic steroids use group,
P¼ 0.105) than in patients who received thymoglobulin
(14.4% in steroid withdrawal and 10.3% in chronic steroid
group, P¼NS). Renal function was no different between the
groups after 5 years. Serious infectious events were more
common in chronic steroid users (16.4 vs 9.4%, P¼ 0.04).
Post hoc analysis did reveal a 5.8% increase in chronic
allograft nephropathy in the steroid withdrawal group over
5 years (9.9 vs 4.1%, P¼ 0.028). However, this last
observation needs to be interpreted cautiously, as neither
baseline nor protocol biopsies were part of the study
protocol. Thus, a possibility of preexisting donor disease
and/or overdetection bias could not be excluded, as a greater
proportion of patients from the steroid withdrawal group
underwent biopsy (46.1 vs 32.8%, respectively, P¼ 0.009).
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The impact of chronic allograft nephropathy on the outcome
remains unknown from this study. A longer follow-up may
help further delineate this aspect.
Finally, Tan et al.38 reported their 3-year experience with
steroid-free Tac monotherapy under alemtuzumab induction.
They reported 3-year patient and graft survival at 93.3 and
86.3%, respectively. The incidence of acute cellular rejection
was low within the first year (9.0%). However, the cumulative
incidence of acute cellular rejection increased to as high as
24% within 3 years after transplantation. Late occurrence of
acute cellular rejection, particularly within the second year,
was especially detrimental to patient and graft survival. It is
important to point out that, in addition to being steroid free,
their protocol also incorporated a spaced weaning of Tac.
Two important questions remain with regard to all these
clinical trials, randomized or not. First, what is the impact of
the increased incidence of acute rejection in steroid with-
drawal patients on long-term graft and patient survival?
Second, are patients who experienced acute rejection system-
atically different from patients who did not experience acute
rejection after steroid withdrawal? Many centers have
established certain criteria for selecting patients for steroid-
free immunosuppression. The criteria became more inclusive
in some centers as they gained experience.23,31,33,39 The risk
factors for acute rejection seemed similar for patients in
steroid-free regimens as for those in steroid-containing
regimens. Certain patients started on steroid-free regimens
would have benefited from steroids once they experienced an
episode of acute rejection.40,41
EPIDEMIOLOGICAL EVIDENCE OF FEASIBILITY IN
STEROID-FREE IMMUNOSUPPRESSION
As of 2006, more than 32% of new kidney transplant patients
in the United States were discharged from initial transplant
without a steroid preparation in their recorded immuno-
suppressive medications. We performed an analysis using
national registry data on the outcome of kidney transplant
performed between 2000 and 2006.17 The study provided a
big picture at the national level on the use of steroid-free
immunosuppression and its impact on outcome. A total of
16,491 patients were discharged without steroids in their
immunosuppressive regimens after transplant surgery. These
patients seemed systematically different from those patients
discharged with steroids in their immunosuppressive regi-
mens, suggesting a selection process that governed the
decision of placing a patient on steroid-free immunosup-
pression at individual centers. With the presence of such a
selection bias, after a 4-year follow-up, graft survival and
patient survival were comparable between patients dis-
charged with and without steroids (Figures 2a and b).
Adjusting for multiple confounders, Cox regression analyses
showed a reduced risk for graft failure and patient death for
patients discharged on steroid-free immunosuppression at
1 and 4 years. Furthermore, there was a wide variation in
the adoption of steroid-free regimens across centers in the
United States and such a variation seemed to influence the
outcome. In fact, when transplant centers were grouped
according to the percentage of patients discharged with
steroids and used as a covariate replacing the indicator of
individual steroid usage in the model, the risk reduction for
graft failure is greatest in centers in which 35 to 80% of
patients were discharged on steroid-free regimens. This again
suggests the importance of patient selection for steroid-free
regimens to achieve the desired outcome.
EVIDENCE FOR POTENTIAL BENEFITS OF STEROID-FREE
IMMUNOSUPPRESSION
The most compelling rationale for steroid-free immuno-
suppression has been reducing cardiovascular disease risks
to which kidney transplant patients are chronically exposed. 6,42
Several clinical trials have shown the potential for
cardiovascular risk reduction, whereas others failed to show
such a benefit. The mean plasma concentration of total
cholesterol and triglyceride improved in some studies but
not in others. This is possibly related to the choice of
maintenance regimens other than steroids.18,19,23,24,29,37
Similarly, blood pressure control was improved and/or the
amounts of antihypertensive medication were reduced in
some but not all studies.18,19,23,43
New-onset diabetes, one of the common complications
after kidney transplantation, is associated with increased
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Figure 2 |Outcome of kidney transplant patients discharged
with and without steroids during 2000 and 2006. (a) Adjusted
graft and (b) patient survival for kidney transplant patients
discharged with and without steroids during 2000 and 2006.
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major cardiovascular events and reduced patient survival.44–46
The diabetogenic effect of steroids has been well recognized
since the early era of kidney transplantation.47–49 The use of
calcineurin inhibitors, CsA and Tac, also contributes to the
risk for new-onset diabetes, with Tac being more diabeto-
genic than CsA.44 As Tac is the most commonly used
calcineurin inhibitor in a steroid-free regimen, the potential
benefit of a steroid-free regimen on new-onset diabetes may
be counterbalanced by the stronger diabetogenic effect of Tac.
The majority of recent steroid-free clinical trials have shown
some improvement in the incidence of new-onset diabetes
and/or glucose control, although a small number of patients
were involved in most of the studies.29,31,33,37 On a large
scale, we have observed a reduced incidence of new-onset
diabetes among kidney transplant patients discharged on
steroid-free immunosuppression within the United States
between 2004 and 2006, compared with those discharged
with steroid-containing immunosuppressive regimens
(15.5 vs 10.2%, respectively, Luan et al., unpublished data).
Two recent clinical studies also suggested that steroid
withdrawal resulted in a reduction in cardiovascular events
and metabolic syndrome.50,51
CONCLUSIONS AND FUTURE DIRECTIONS
Despite the progress made over the past three decades with
steroid-free immunosuppression in kidney transplantation,
there are still lingering questions and concerns. The fact that
concerns many of us is that the incidence of acute rejection
remains, in general, higher in patients receiving steroid-free
immunosuppression than in those receiving steroid-contain-
ing regimens. Long-term graft survival in those who
experienced acute rejection on a steroid-free immunosup-
pressive regimen remains unknown. The real impact of
improvement in conventional cardiovascular disease risk
factors on patient survival has yet to be shown. The fact that
more than 50% of all kidney grafts were lost and more than
30% of all kidney transplant patients died within 10 years
from the time of transplant in the United States underscores
the importance of our effort in defining the best immuno-
suppressive regimens.52 The major challenge remains the
identification of individual patients who may not benefit
from a steroid-free immunosuppressive regimen. Until then,
steroid-free immunosuppression should be considered as a
standard of care only for a carefully selected group of
patients.
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